BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered ...

Ginkgo Bioworks has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium).

BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo ...

Virica Biotech will provide a panel of their cell enhancers for use in high-throughput AAV production screening for Ginkgo’s clients. Ginkgo Bioworks will leverage their advanced screening platform ...

Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue. But if it can survive, Ginkgo could become a ...

BOSTON, Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of ...

Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases Autoimmune diseases, such as ...